James Stoller
Pulmonary Disease · Cleveland, OHNPI 1548227176
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,174 of the $100,653 with a category attached, or 69.7%. 11 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 24.1% of the total. Reporting peaked in 2024 at $23,500 and has fallen 54.5% since, to $10,697 in 2025. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $1156.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Grifols, S.A.$20K
- Sanofi$16K
- Vertex$12K
- Grifols Canada Ltd.$10K
- Grifols USA, LLC$8K
- plus $11K from 5 others
Across 13 payments — averaging $16,878 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$217K
- Shire North American Group Inc$3K
What the payments were for
- Consulting fees$70,17470%
- Speaking & faculty fees$21,47021%
- Grants$2,5002%
- Travel & lodging$5,6466%
- Food & beverage$8271%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $24,305 |
| Grifols, S.A. | 12 | $19,936 |
| Sanofi | 7 | $15,701 |
| Vertex | 18 | $12,486 |
| Grifols Canada Ltd. | 11 | $9,734 |
| Grifols USA, LLC | 3 | $7,800 |
| Medtronic | 2 | $7,500 |
| CSL Behring | 5 | $2,290 |
| Monaghan Medical Corporation | 1 | $541 |
| Biomarin Pharmaceutical Inc. | 1 | $250 |
| Olympus America Inc. | 2 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLASSIA$11,327
- Prolastin-C Liquid$10,800
- Prolastin-C$8,350
- Zemaira$2,254
- AeroEclipse$541
How this compares
$100,653 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $222,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $24,305 | $222,40613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$551K
- Joseph CiceniaCleveland$350K
- Michael MachuzakCleveland$286K
- Marie BudevCleveland$159K
- Leslie TolleCleveland$136K
- Elliott DasenbrookCleveland$114K
- Gustavo Heresi DavilaCleveland$98K
- Bryan BennCleveland$96K
- Thomas GildeaCleveland$69K
- Daniel CulverCleveland$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.